GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Gross Margin %

Rigel Pharmaceuticals (STU:RI2A) Gross Margin % : 93.14% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Rigel Pharmaceuticals's Gross Profit for the three months ended in Mar. 2024 was €25.3 Mil. Rigel Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €27.2 Mil. Therefore, Rigel Pharmaceuticals's Gross Margin % for the quarter that ended in Mar. 2024 was 93.14%.


The historical rank and industry rank for Rigel Pharmaceuticals's Gross Margin % or its related term are showing as below:

STU:RI2A' s Gross Margin % Range Over the Past 10 Years
Min: 93.22   Med: 98.87   Max: 99.36
Current: 93.22


During the past 13 years, the highest Gross Margin % of Rigel Pharmaceuticals was 99.36%. The lowest was 93.22%. And the median was 98.87%.

STU:RI2A's Gross Margin % is ranked better than
90.13% of 750 companies
in the Biotechnology industry
Industry Median: 60.91 vs STU:RI2A: 93.22

Rigel Pharmaceuticals had a gross margin of 93.14% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Rigel Pharmaceuticals was -0.80% per year.


Rigel Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Rigel Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Gross Margin % Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.47 99.18 99.27 98.55 93.92

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.25 96.00 95.49 89.41 93.14

Competitive Comparison of Rigel Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Rigel Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Gross Margin % falls into.



Rigel Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Rigel Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=100.7 / 107.181
=(Revenue - Cost of Goods Sold) / Revenue
=(107.181 - 6.52) / 107.181
=93.92 %

Rigel Pharmaceuticals's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=25.3 / 27.171
=(Revenue - Cost of Goods Sold) / Revenue
=(27.171 - 1.863) / 27.171
=93.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Rigel Pharmaceuticals  (STU:RI2A) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Rigel Pharmaceuticals had a gross margin of 93.14% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Rigel Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines